Efficacy of lasmiditan for the acute treatment of perimenstrual migraine.

ABSTRACT:

Background

Perimenstrual migraine attacks in women with menstrual migraine is difficult to treat. This post-hoc analysis evaluated the efficacy of lasmiditan, a high affinity and selective 5-HT_1F receptor agonist, for perimenstrual attacks.

Methods

Patients from two randomized, double-blind, placebo-controlled clinical trials (MONONOFU and CENTURION) were instructed to treat an attack with a single dose of study medication within four hours of pain onset. After dosing, the proportion of patients who achieved freedom from migraine-related head pain, most bothersome symptom, and disability was reported at baseline up to 48 hours after dose and pooled data were evaluated.

Results

A total of 303 patients (MONONOFU N = 78; CENTURION N = 225) treated perimenstrua

SUBMITTER: MacGregor EA 

PROVIDER: S-EPMC9693902 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature